HCP-1803 is under clinical development by Hanmi Pharmaceuticals and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData, Phase III drugs for Idiopathic (Essential) ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA) trial of a drug it is developing with Korea’s Hanmi Pharmaceuticals, according to press reports. The Korea Biomedical Review cited ...

A study published in Nature Medicine looks at the health risks and benefits linked to GLP-1 receptor agonists. Prof Naveed Sattar, Professor of Cardiometabolic Medicine/Honorary Consultant, University ...

It was licensed from South Korea’s Hanmi Pharma in 2016 for $80 million upfront – when it was also in early-stage – in a deal worth up to $910 million. Hanmi, which retained rights to the ...

In October 2023, SpyGlass Pharma announced the initiation of a Phase I/II clinical trial investigating its intraocular drug delivery platform in patients with glaucoma and visually significant ...

DelveInsight’s 'Ocular Hypertension Pipeline Insight 2025' report provides comprehensive global coverage of pipeline ocular hypertension therapies in various stages of clinical development, major ...

As more Asia biotechs turn to regenerative medicine to address disorders without a cure, Medipost Inc. is continuing global ...

Hanmi Financial Price Performance Shares of Hanmi Financial stock opened at $22.74 on Tuesday. The stock has a market cap of $686.75 million, a price-to-earnings ratio of 10.93 and a beta of 0.89 ...

Hanmi Financial Trading Up 0.5 % Shares of HAFC stock opened at $22.74 on Tuesday. The firm has a market capitalization of $686.75 million, a PE ratio of 10.93 and a beta of 0.89. The company has ...